- Home
- ILAG vs SNSE Comparison
ILAG vs SNSE Comparison
Compare ILAG & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- SNSE
- Stock Information
- Founded
- ILAG 1981
- SNSE 2005
- Country
- ILAG Hong Kong
- SNSE United States
- Employees
- ILAG N/A
- SNSE N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- SNSE Health Care
- Exchange
- ILAG Nasdaq
- SNSE Nasdaq
- Market Cap
- ILAG 12.1M
- SNSE 14.5M
- IPO Year
- ILAG 2022
- SNSE 2021
- Fundamental
- Price
- ILAG $0.58
- SNSE $9.17
- Analyst Decision
- ILAG
- SNSE Strong Buy
- Analyst Count
- ILAG 0
- SNSE 5
- Target Price
- ILAG N/A
- SNSE $72.50
- AVG Volume (30 Days)
- ILAG 38.2K
- SNSE 79.1K
- Earning Date
- ILAG 12-19-2025
- SNSE 11-07-2025
- Dividend Yield
- ILAG N/A
- SNSE N/A
- EPS Growth
- ILAG N/A
- SNSE N/A
- EPS
- ILAG N/A
- SNSE N/A
- Revenue
- ILAG $7,506,551.00
- SNSE N/A
- Revenue This Year
- ILAG N/A
- SNSE N/A
- Revenue Next Year
- ILAG N/A
- SNSE N/A
- P/E Ratio
- ILAG N/A
- SNSE N/A
- Revenue Growth
- ILAG 16.50
- SNSE N/A
- 52 Week Low
- ILAG $0.34
- SNSE $5.00
- 52 Week High
- ILAG $1.09
- SNSE $18.35
- Technical
- Relative Strength Index (RSI)
- ILAG 48.78
- SNSE 44.10
- Support Level
- ILAG $0.54
- SNSE $9.07
- Resistance Level
- ILAG $0.65
- SNSE $12.40
- Average True Range (ATR)
- ILAG 0.04
- SNSE 2.09
- MACD
- ILAG -0.00
- SNSE -0.44
- Stochastic Oscillator
- ILAG 69.23
- SNSE 8.37
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).